TY - JOUR
T1 - CTCAE v3.0
T2 - Development of a comprehensive grading system for the adverse effects of cancer treatment
AU - Trotti, Andy
AU - Colevas, A. Dimitrios
AU - Setser, Ann
AU - Rusch, Valerie
AU - Jaques, David
AU - Budach, Volker
AU - Langer, Corey
AU - Murphy, Barbara
AU - Cumberlin, Richard
AU - Coleman, C. Norman
AU - Rubin, Philip
N1 - Funding Information:
Supported by NCI R13 CA 93030-01.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2003/7
Y1 - 2003/7
N2 - Multiple systems have been developed for grading the adverse effects (AEs) of cancer treatment. The National Cancer Institute Common Toxicity Criteria (CTC) system has substantially evolved since its inception in 1983. The most recent version, CTCAE v3.0 (Common Terminology Criteria for Adverse Events version 3.0) represents the first comprehensive, multimodality grading system for reporting the acute and late effects of cancer treatment. The new CTC requires changes in the application of AE criteria including new guidelines regarding late effects, surgical and pediatric effects, multimodality issues, and for reporting the duration of an effect. It builds on the strengths of previous systems, represents a considerable effort among hundreds of participants, and signifies an international collaboration and consensus of the oncology research community. This article updates recent progress in the evolution of adverse effects grading systems and reviews the development of CTCAE v3.0.
AB - Multiple systems have been developed for grading the adverse effects (AEs) of cancer treatment. The National Cancer Institute Common Toxicity Criteria (CTC) system has substantially evolved since its inception in 1983. The most recent version, CTCAE v3.0 (Common Terminology Criteria for Adverse Events version 3.0) represents the first comprehensive, multimodality grading system for reporting the acute and late effects of cancer treatment. The new CTC requires changes in the application of AE criteria including new guidelines regarding late effects, surgical and pediatric effects, multimodality issues, and for reporting the duration of an effect. It builds on the strengths of previous systems, represents a considerable effort among hundreds of participants, and signifies an international collaboration and consensus of the oncology research community. This article updates recent progress in the evolution of adverse effects grading systems and reviews the development of CTCAE v3.0.
UR - http://www.scopus.com/inward/record.url?scp=10744228140&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10744228140&partnerID=8YFLogxK
U2 - 10.1016/S1053-4296(03)00031-6
DO - 10.1016/S1053-4296(03)00031-6
M3 - Article
C2 - 12903007
AN - SCOPUS:10744228140
SN - 1053-4296
VL - 13
SP - 176
EP - 181
JO - Seminars in Radiation Oncology
JF - Seminars in Radiation Oncology
IS - 3
ER -